Latest & greatest articles for hydroxychloroquine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydroxychloroquine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydroxychloroquine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydroxychloroquine

1. Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19

Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19 Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19 - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19 March 25, 2020 KERSTIN FRIE and KOME GBINIGIE Oxford COVID-19 (...) Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford Correspondence to oghenekome.gbinigie@phc.ox.ac.uk 26/03/2020 VERDICT Several in vitro studies report antiviral activity of chloroquine and hydroxychloroquine against SARS-CoV-2. In vivo data, although promising, is currently limited to one study with considerable limitations. On the basis of the weak evidence available to date, treatment guidelines have already

2020 Oxford COVID-19 Evidence Service

2. Statistical review of Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Statistical review of Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial application/octet-stream

2020 Covid-19 Ad hoc papers

3. Is hydroxychloroquine (with or without azithromycin) effective in treating COVID-19?

Is hydroxychloroquine (with or without azithromycin) effective in treating COVID-19? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care (...) research. www.acfp.ca March 30, 2020 COVID-19 Rapid Reviews Along with regular Tools for Practice, the PEER team will be writing rapid reviews to address COVID-19 topics relevant for primary care. The evidence is changing rapidly and it is possible that as you read this, new evidence will already be available. We will try our best to stay in front and keep you up-to- date during these challenging times. Hydrochloroquine with or without azithromycin for COVID-19 Clinical Question: Is hydroxychloroquine

2020 Tools for Practice

4. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries Redirecting

2020 Covid-19 Ad hoc papers

5. [Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL]. (Abstract)

[Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL]. Antiphospholipid syndrome is defined by the presence of thrombosis and/or obstetrical adverse events (≥3 recurrent early miscarriage or fetal death or a prematurity<34 weeks of gestation) associated with persistent antiphospholipid antibodies. The pregnancy outcome has been improved by the conventional treatment (aspirin 100mg (...) anticoagulant and APL triple positivity are considered as factors associated with unfavorable obstetrical outcome. Hydroxychloroquine (HCQ) has anti-inflammatory and anti-thrombotic properties. Studies in vitro have shown that HCQ is able to restore the placental expression of Annexin V, which has an anticoagulant effect and to prevent the placental injury induced by APL. HCQ used for lupus erythematosus decrease the thrombotic risk and its value for thrombotic APS has been raised in an open labelled French

2018 Gynecologie, obstetrique, fertilite & senologie Controlled trial quality: uncertain

6. Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial Full Text available with Trip Pro

Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial To determine the symptom-modifying effect of hydroxychloroquine (HCQ) in hand osteoarthritis (OA).In this randomized, double-blind, multicenter trial, patients with symptomatic hand OA received either HCQ 400 mg once a day or placebo during 24 weeks. The primary outcome was change of pain measured on a 100-mm visual analog scale (VAS) at 24 weeks. Secondary outcomes included decrease

2018 EvidenceUpdates

7. Hydroxychloroquine

Hydroxychloroquine Top results for hydroxychloroquine - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hydroxychloroquine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

8. A case of exogenous ochronosis associated with hydroxychloroquine Full Text available with Trip Pro

A case of exogenous ochronosis associated with hydroxychloroquine Exogenous ochronosis is characterized by hyperpigmented skin lesions that arise in association with local suppression of homogentisic acid oxidase enzyme. Although it generally develops in association with topical application of chemical agents, it can occasionally develop in association with antimalarial drugs. Here we present the case of a patient with rheumatoid arthritis who developed hyperpigmentation on the face and neck (...) regions during hydroxychloroquine treatment. Hydroxychloroquine is being widely used in rheumatology practice, and cutaneous hyperpigmentation may develop as an adverse effect. In the present case, we emphasize the potential underlying mechanisms through which it may cause cutaneous hyperpigmentation and determine the clinical and histopathological findings of exogenous ochronosis.

2018 European journal of rheumatology

9. Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis: A Randomized Trial. Full Text available with Trip Pro

Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis: A Randomized Trial. Synovitis is believed to play a role in producing symptoms in persons with hand osteoarthritis, but data on slow-acting anti-inflammatory treatments are sparse.To determine the effectiveness of hydroxychloroquine versus placebo as an analgesic treatment of hand osteoarthritis.Randomized, double-blind, placebo-controlled clinical trial with 12-month follow-up. (ISRCTN registry number: ISRCTN91859104 (...) numerical rating scale [NRS]) at 6 months. Secondary end points included self-reported pain and function, grip strength, quality of life, radiographic structural change, and adverse events. Baseline ultrasonography was done.At 6 months, mean hand pain was 5.49 points in the placebo group and 5.66 points in the hydroxychloroquine group, with a treatment difference of -0.16 point (95% CI, -0.73 to 0.40 point) (P = 0.57). Results were robust to adjustments for adherence, missing data, and use of rescue

2018 Annals of Internal Medicine Controlled trial quality: predicted high

10. Pericentral hydroxychloroquine retinopathy in a Caucasian female Full Text available with Trip Pro

Pericentral hydroxychloroquine retinopathy in a Caucasian female To report a rare presentation of the pericentral pattern of hydroxychloroquine (HCQ) retinal toxicity in a Caucasian female.The patient presented with 20 years of exposure to HCQ, at a daily dose of 5.2mg/kg of actual body weight, and manifested a pericentral-only phenotype of HCQ toxicity, as demonstrated with detailed structural and functional testing.Although rare, the pericentral pattern of HCQ toxicity may occur in Caucasian

2018 American journal of ophthalmology case reports

11. Hydroxychloroquine and Chloroquine Retinopathy Screening

Hydroxychloroquine and Chloroquine Retinopathy Screening Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Screening Clinical Guidelines February 2018 Review date: February 2021The Royal College of Ophthalmologists (RCOphth) is the professional body for eye doctors, who are medically qualified and have undergone or are undergoing specialist training in the treatment and management of eye disease, including surgery. As an independent charity, we pride ourselves on providing (...) Management of Patients with Possible Retinopathy 7 2.6 Management of Patients with Definite Toxicity 8 2.7 Termination of Screening 8 2.8 Organisation of Services 8 2.9 Work Commitment 8 3. Screening for hydroxychloroquine retinopathy: Lay Summary 9 4. Introduction 11 4.1 Population to whom the Guideline applies e.g. the age range, gender, clinical description (ICD10) and co-morbidity (ICD10) and any exclusions 12 4.2 Paediatric Indications for Screening 12 4.3 Current practice, and why there is scope

2018 Royal College of Ophthalmologists

12. Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. Full Text available with Trip Pro

Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. Inflammation of the arterial wall plays a central role in the pathogenesis of atherosclerosis. Among patients with rheumatic diseases, anti-rheumatic medication reduces the incidence of cardiovascular (CV) diseases, but only few studies have addressed their cardioprotective effects on patients with no rheumatic diseases. Hydroxychloroquine (HCQ

2016 European heart journal. Cardiovascular pharmacotherapy Controlled trial quality: uncertain

13. Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS. Full Text available with Trip Pro

Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS. Hydroxychloroquine (HCQ), 4-aminoquinoline, is an antimalarial drug and has become a basic therapy for rheumatic disease treatment. It can stabilize the condition of SLE patients and reduce the chances of patient relapse through its immunosuppressive function and antiinflammatory effects. This drug was absorbed completely and rapidly by oral administration, but has (...) to receive 0.2 g hydroxychloroquine sulfate tablets (0.1 g/piece) of the two formulations after a 3-month washout period then administered the alternate formulation. Study drugs were administered after overnight fasting (over 10 h). Plasma concentrations of hydroxychloroquine were measured by a validated LC-MS/MS method. The following pharmacokinetic properties were determined by a noncompartmental pharmacokinetic method: C max, T max, AUC0-t , AUC0-∝, and t 1/2. The bioequivalence between the test

2016 Rheumatology and therapy Controlled trial quality: uncertain

14. Plaquenil (hydroxychloroquine sulfate) - Long-acting symptomatic treatment of rheumatoid arthritis, Discoid lupus erythematosus, Subacute lupus erythematosus, systemic lupus erythematosus, Prevention of polymorphous light eruption

Plaquenil (hydroxychloroquine sulfate) - Long-acting symptomatic treatment of rheumatoid arthritis, Discoid lupus erythematosus, Subacute lupus erythematosus, systemic lupus erythematosus, Prevention of polymorphous light eruption HAS - Medical, Economic and Public Health Assessment Division 1/11 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 23 July 2014 PLAQUENIL 200 mg, film-coated tablet B/30 (CIP: 34009 364 (...) 414 6 0) Applicant: SANOFI-AVENTIS France INN hydroxychloroquine sulfate ATC code (2014) P01BA02 (synthetic antimalarials) Reason for the review Renewal of inclusion List concerned National Health Insurance (French Social Security Code L.162-17) Indications concerned “Long-acting symptomatic treatment of rheumatoid arthritis, Discoid lupus erythematosus, Subacute lupus erythematosus, Adjuvant or preventive treatment of relapses of systemic lupus erythematosus, Prevention of polymorphous light

2015 Haute Autorite de sante

15. Hydroxychloroquine in the Treatment of Osteoarthritis

Hydroxychloroquine in the Treatment of Osteoarthritis "Hydroxychloroquine in the Treatment of Osteoarthritis" by Briana Hougum < > > > > > Title Author Date of Graduation Summer 8-8-2015 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers, MS, PA-C Rights . Abstract Background : Osteoarthritis (OA) accounts for one of the most common causes of loss of work and disability in America. Traditional treatments are aimed (...) at symptomatic relief and maintaining functional capacity, but have not been shown to modify disease progression. Evidence for inflammatory and immune components in the development of OA lend support to expanding treatment options to potentially slow the disease and delay the need for invasive surgical intervention. Hydroxychloroquine (HCQ) is known for its use as an antimalarial and as a DMARD for rheumatoid arthritis, but has also been considered an option for treatment resistant OA. Several studies have

2015 Pacific University EBM Capstone Project

16. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. Full Text available with Trip Pro

Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. Primary Sjögren syndrome is a systemic autoimmune disease characterized by mouth and eye dryness, pain, and fatigue. Hydroxychloroquine is the most frequently prescribed immunosuppressant for the syndrome. However, evidence regarding its efficacy is limited.To evaluate the efficacy of hydroxychloroquine for the main symptoms of primary Sjögren syndrome: dryness, pain (...) , and fatigue.From April 2008 to May 2011, 120 patients with primary Sjögren syndrome according to American-European Consensus Group Criteria from 15 university hospitals in France were randomized in a double-blind, parallel-group, placebo-controlled trial. Participants were assessed at baseline, week 12, week 24 (primary outcome), and week 48. The last follow-up date for the last patient was May 15, 2012.Patients were randomized (1:1) to receive hydroxychloroquine (400 mg/d) or placebo until week 24. All

2014 JAMA Controlled trial quality: predicted high

17. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study) (Abstract)

Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study) Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE). Its blood concentration ([HCQ]) varies widely between patients and is a marker and predictor of SLE flares. This prospective randomised, double-blind, placebo-controlled, multicentre study sought to compare standard and adjusted HCQ dosing schedules that target [HCQ] ≥1000 ng/ml

2013 EvidenceUpdates Controlled trial quality: predicted high

18. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial (Abstract)

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial To compare EuroQol 5-Dimensions (EQ-5D) utility and quality-adjusted life-years (QALYs) in patients with early, methotrexate (MTX) refractory rheumatoid arthritis (RA), randomised to addition of infliximab (IFX) or sulfasalazine and hydroxychloroquine (SSZ+HCQ).RA-patients with symptoms <1

2012 EvidenceUpdates Controlled trial quality: uncertain

19. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. Full Text available with Trip Pro

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. Therapies to decrease immune activation might be of benefit in slowing HIV disease progression.To determine whether hydroxychloroquine decreases immune activation and slows CD4 cell decline.Randomized, double-blind, placebo-controlled trial performed at 10 HIV outpatient clinics in the United Kingdom between June 2008 (...) was no significant difference in CD8 cell activation between the 2 groups (-4.8% and -4.2% in the hydroxychloroquine and placebo groups, respectively, at week 48; difference, -0.6%; 95% CI, -4.8% to 3.6%; P = .80). Decline in CD4 cell count was greater in the hydroxychloroquine than placebo group (-85 cells/μL vs -23 cells/μL at week 48; difference, -62 cells/μL; 95% CI, -115 to -8; P = .03). Viral load increased in the hydroxychloroquine group compared with placebo (0.61 log10 copies/mL vs 0.23 log10 copies/mL

2012 JAMA Controlled trial quality: predicted high

20. Hydroxychloroquine and ocular toxicity recommendations on screening

Hydroxychloroquine and ocular toxicity recommendations on screening The Royal College of Ophthalmologists - Hydroxychloroquine and Ocular Toxicity Recommendations on Screening – October 2009 Page 1 of 9 The Royal College of Ophthalmologists Hydroxychloroquine and Ocular Toxicity Recommendations on Screening October 2009 Scientific Department The Royal College of Ophthalmologists 17 Cornwall Terrace Regent’s Park London NW1 4QW Telephone: 020 7935 0702 Facsimile: 020 7487 4674 www.rcophth.ac.uk (...) The Royal College of Ophthalmologists - Hydroxychloroquine and Ocular Toxicity Recommendations on Screening – October 2009 Page 2 of 9 Hydroxychloroquine and Ocular Toxicity Recommendations on Screening (Replacing the Royal College of Ophthalmologists Guidelines for Screening 2004 and 1998) Background Hydroxychloroquine is a quinolone used primarily by rheumatologists for rheumatoid arthritis and systemic lupus erythematosus, and by dermatologists for cutaneous lupus. Although its mechanism of action

2009 British Association of Dermatologists